Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QHRD107 Combined with Venetoclax and Azacitidine in R/R AML
NCT06532058Phase 2Recruiting
- Sponsor
- Changzhou Qianhong Biopharma Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QHRD107 in acute myeloid leukemia (AML), sponsored by Changzhou Qianhong Biopharma Co., Ltd.. Started Aug 2023; status: recruiting.
02
Drugs
QHRD107
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06532058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532058.